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Natural productIn connection with prospective 18F-PET imaging studies, the potential for enzymatic synthesis of ﬂuorine-
labelled glycosides of small molecules was investigated. Approaches to the enzymatic synthesis of
anomeric phosphates of D-gluco-conﬁgured ﬂuorosugars proved ineffective. In contrast, starting in the
D-galacto series and relying on the consecutive action of Escherichia coli galactokinase (GalK), galact-
ose-1-phosphate uridylyltransferase (GalPUT), uridine-50-diphosphogalactose 4-epimerase (GalE) and
oat root glucosyltransferase (SAD10), a quick and effective synthesis of 6-deoxy-6-ﬂuoro-D-glucosyl
N-methylanthranilate ester was achieved.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction the use of [18F]ﬂuorosugars for labelling. Although the most widelyFluorine is an effective probe substituent that has found applica-
tions in a variety of different ﬁelds. Its chemical and physical prop-
erties make this element particularly interesting for NMR studies in
organic and biological structural analysis and for bio-imaging tech-
niques, such as magnetic resonance imaging (MRI) and positron
emission tomography (PET), providing a wider range of chemical
shifts and greater sensitivity when compared to hydrogen.1 In par-
ticular, 18F-PET has emerged as an important technique, not only for
medical diagnosis and evaluation of treatment progress but also for
understanding the mechanisms by which a biological activity is
elicited. In this context, it represents a promising approach for
imaging and quantitative assessment of the metabolic fate and
accumulation sites of bioactive compounds, including drugs and
nutraceuticals. 18F-PET enables non-invasive in vivo analysis with-
out tissue destruction and without being inﬂuenced by the compo-
sition of the tissue studied.2 In this context, great effort has recently
been devoted to the development of new and efﬁcient strategies for
the introduction of 18F atoms into peptides3–8 and metabolites of
interest.9,10 The majority of the developed methodologies rely onused is 2-deoxy-2-[18F]ﬂuoro-D-glucose, since is the common tracer
for PET imaging and it is the primary source of 18F for nuclear med-
icine, other isomers of deoxy-ﬂuoroglucose11,12 as well as other ﬂu-
orosugars,13 may be considered.
As the demand for new and effective strategies for introduction
of 18F into tracers is increasing, the use of enzymatic routes is
becoming more appealing due to the speciﬁcity of the reaction,
leading to straightforward recovery of the desired products.
Glycosyltransferases (GTs) are widespread enzymes in Nature with
thousands of sequences already reported in different organisms
(CAZy database).14 They catalyse the transfer of a sugar residue
from an activated sugar donor, such as a nucleoside diphospho-
sugar, to an acceptor. The acceptor substrates utilized by GTs are
commonly other sugars, but can also be lipids, proteins, nucleic
acids, antibiotics, or other small molecules. The glycosylation
reaction can occur with –OH groups (most commonly) but it can
also occur with –COOH, –NH2, –SH, and activated aromatic
groups.15–18 Some GTs are highly speciﬁc and are able to recognise
only one or a limited range of acceptor substrates, whereas other
GTs are promiscuous and can glycosylate a broad range of accep-
tors. GTs are considered useful synthetic tools for the preparation
of natural oligosaccharides, glycoconjugates and their analogues;19
they are potentially interesting catalyst candidates for 18F radio-
chemistry, although their use may depend on the availability and
suitability of an activated sugar donor.
Although ﬂuorinated sugars have proved to be invaluable
probes and inhibitors of glycosidases,20 the impact of sugar ﬂuori-
nation on glycosyltransferase-mediated glycosyl transfer is rather
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site of ﬂuorine substitution but also on the type and source of the
transferase in question. Before discussing the literature, a note of
caution is required: the time windows and sugar nucleotide con-
centrations employed in some literature reports, particularly
where ﬂuorinated compounds are assessed as potential inhibitors,
may not be compatible with forcing the turn-over of much less
reactive ﬂuorinated substrates. Hence reports of ‘no turn-over’
need to be considered in context. As would be expected, given
the electronic impact of electron withdrawing ﬂuorine adjacent
to an acetal centre, sugar nucleotides bearing a ﬂuorine atom at
either the 2 or 5 position of the sugar ring do not generally serve
as glycosyltransferase substrates, but they are effective competi-
tive inhibitors of such enzymes.21–23 However, it has been reported
that, in preparative biotransformations, GDP-2-deoxy-2-ﬂuoro-L-
fucose is indeed a substrate for FucTIII, although the same mole-
cule is not a substrate for FucTVI.24 The metabolic incorporation
of 4-deoxy-4-ﬂuoro-GlcNAc into UDP-4-deoxy-4-ﬂuoro-GlcNAc
has been demonstrated in the human prostate cancer cell line
PC-3. This leads to a metabolic block, since the ﬂuorinated sugar-
nucleotide is unable to transfer the ﬂuorosugar to N-glycans, in-
stead serving as a competitive inhibitor of natural sugar transfer
and impacting on N-glycan proﬁles.25 GDP-6-ﬂuoro-L-fucose is a
competitive inhibitor of human fucosyltransferases III, V, VI and
VII21 and recombinant porcine a-1,3-GalT and bovine milk b-1,4-
GalT are unable to transfer 6-deoxy-6-ﬂuoro-D-galactose onto an
acceptor.26 In a similar vein, 6-deoxy-6-ﬂuoro-D-glucose-1-phos-
phate is a very poor donor substrate for glycogen phosphorylase,
displaying a 750,000 fold reduction in Vmax/Km with respect to
the parent glucose-1-phosphate.27 In contrast, the bacterial glyco-
syltransferase OleD (but not OleI or MGT) has been reported toO
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Figure 1. Outline of enzymatic approaches. (A) Hexokinase-phosphoglucomutase appro
Galactokinase-uridylyltransferase-epimerase approach from Gal.transfer 6-deoxy-6-ﬂuoro-D-galactose from the corresponding
UDP-sugar adduct onto the glycosylated macrolide oleandomy-
cin28 and, operating in the reverse sense, the OleD TDP-16 variant
is able to produce UDP-6-deoxy-6-ﬂuoro-D-galactose from the cor-
responding 2-chloro-4-nitro-phenyl glycoside.29 Further, UDP-5-
deoxy-5-ﬂuoro- and UDP-6-deoxy-6-ﬂuoro-D-galactofuranose
have been shown to serve as donor substrates and acceptor chain
termination agents for Mycobacterial GlfT2.30
As is evident from this brief survey, the impact of donor substrate
ﬂuorination on glycosyltransferase-mediated glycosyl transfer is
somewhat unpredictable. We were therefore minded to further
investigate the potential of enzymatic synthesis to prepare sugar
nucleotides substituted with ﬂuorine, eventually settling on sub-
strates substituted at the 6-position of the sugar to be transferred.
The6-ﬂuorinated compoundwasalsoevaluatedasadonor substrate
for a representative glycosyltransferase, in this case the oat transfer-
aseSAD10, thephysiological roleofwhich is associatedwith thegen-
eration of an O-glucosyl N-methylanthranilate ester.31 Here we
report an assessment of enzymatic approaches to 1-O-(N-methy-
lanthraniloyl)-6-deoxy-6-ﬂuoro-b-D-glucopyranose (6F-Glc-NMA).
We report a convenient multi-enzyme biotransformation approach
for generation of UDP-6-deoxy-6-ﬂuoro-D-glucose (UDP-6F-Glc)
and the subsequent glycosyltransferase-catalysed transfer of 6-
deoxy-6-ﬂuoro-D-glucose onto N-methylanthranilate. The strategy
developedand theassociated timeframesare compatiblewithambi-
tions to synthesise 18F-labelled materials for PET imaging studies.
2. Results and discussion
In order to investigate the ability of GTs to produce ﬂuorine-la-
belled glycosides, we had a need to generate the correspondingO
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Figure 2. (A–D) 1H NMR signals of the anomeric protons H100 and H1. (A) GalE
mediated epimerisation of UDP-D-Gal into UDP-D-Glc. Lower trace, no enzyme (NE)
control; upper trace, time point 1 h (UDP-Gal/UDP-Glc 1.0:3.8). (B) GalE mediated
epimerisation of UDP-6F-D-Gal into UDP-6F-D-Glc. Lower trace, no enzyme; upper
trace, time point 1 h (1.0:2.0). (C) SAD10 mediated transformation of UDP-D-Glc and
N-methylanthranilic acid to give 1-O-(N-methylanthraniloyl)-b-D-glucopyranose
(Glc-NMA). Lower trace, no enzyme; upper trace, time point 1 h (12% conversion).
(D) SAD10 mediated transformation of UDP-6F-D-Glc and N-methylanthranilic acid
to give 1-O-(N-methylanthraniloyl)-6-deoxy-6-ﬂuoro-b-D-glucopyranose (6F-Glc-
NMA). Lower trace, no enzyme; upper trace, time point 1 h (21% conversion). (C
and D) The minor impurities (dd) are the residual galacto-conﬁgured sugar
nucleotides starting materials.
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precedent for efﬁcient C-2 ﬂuorination via glycal chemistry,32 but
the detrimental impact of installation of the electronic withdraw-
ing ﬂuorine adjacent to the anomeric centre, we surmised that ease
and speed of ﬂuorination at the hexose primary alcohol would
represent a practical way forward. With this in mind, a number
of enzymatic strategies were trialled (Fig. 1), with the aim ofO
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Figure 3. One-pot, multi-enzyme synthesis of 1-O-(N-methylanthidentifying the approaches that would be compatible with the
short half-life of an 18F-labelled sugar (18F half-life 110 min).
2.1. The hexokinase-phosphoglucomutase approach
We initially explored the possibility of combining the phos-
phorylating activity of hexokinase to generate the glucose-6-phos-
phates (incompatible with the use of the 6-ﬂuorosugar) with that
of phosphoglucomutase, which transfers the phosphate from the
6-position to the 1-position. Subsequent action of galactose-1-
phosphate uridylyltransferase would then give the desired sugar
nucleotide (Fig. 1A). Employing the commercial yeast hexokinase
and rabbit muscle phosphoglucomutase enzymes, this approach
provided only very low conversion when starting from 3-deoxy-
3-ﬂuoro-D-glucose or 4-deoxy-4-ﬂuoro-D-glucose. A similar ap-
proach has been reported by Prante et al.,33 when synthesizing
UDP-2-deoxy-2-ﬂuoro-D-glucose. However, the authors reported
a conversion of 50% of the substrate in 6 days—far too long for
applications involving the use of 18F. The ineffectiveness of the
hexokinase-phosphoglucomutase approach could be ascribed to
the fact that ﬂuorosugars act as slow substrates for the hexokinase
and phosphoglucomutase.
2.2. The mutant galactokinase-uridylyltransferase approach
A multi-enzyme method with recycling of the co-factors devel-
oped by Liu et al.,34 later modiﬁed by Errey et al.,35 starting from
the reducing sugars was also evaluated (Fig. 1B). This method relies
on two key enzymes, galactokinase (GalK) and galactose-1-phos-
phate uridylyltransferase (GalPUT). As shown before35 GalPUT pos-
sesses a broad substrate promiscuity. GalK, however, displays a
high stringency for the C4-axial D-galacto-conﬁguration of the su-
gar substrate, not recognizing d-glucose, for example. In a ﬁrst
set of experiments, the M173L-Y371H Escherichia coli GalK double
mutant36 was investigated to directly phosphorylate ﬂuorinated
monosaccharides at the C1 position. This enzyme has previously
been shown to possess relatively relaxed substrate recognition,
allowing the direct anomeric phosphorylation of sugars with the
C4-equatorial D-gluco-conﬁguration. However, in our hands this
approach was not effective in producing D-gluco-conﬁgured ano-
meric phosphates from glucose substituted with ﬂuorine at the 3,
4 or 6 position, although the recombinant enzyme proved to be a
competent galactokinase. In this instance perhaps the kineticO
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raniloyl)-6-deoxy-6-ﬂuoro-b-D-glucopyranose (6F-Glc-NMA).
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biotransformation of ﬂuorinated D-gluco-conﬁgured sugars.
2.3. The galactokinase-uridylyltransferase-epimerase approach
Unable to achieve either the indirect or direct anomeric enzy-
matic phosphorylation of gluco-conﬁgured ﬂuorosugars, we next
approached the problem from a different angle (Fig. 1C). 6-
Deoxy-6-ﬂuoro-D-galactose, which we have previously shown to
be a good substrate for wild-type GalK, was successfully converted
into UDP-6-deoxy-6-ﬂuoro-D-galactose (UDP-6F-D-Gal) (Fig. 3) fol-
lowing a multi-enzyme protocol, as reported previously.35,37 This
sugar nucleotide was then transformed into UDP-6F-D-Glc by the
action of uridine-50-diphosphogalactose 4-epimerase (GalE). This
enzyme catalyzes the ﬁnal step of the highly conserved Leloir
pathway of galactose metabolism, epimerising the C4 position of
UDP-galactose (UDP-Gal) to give UDP-glucose (UDP-Glc). GalE
from galactose-adapted yeast was used and a control reaction,
the epimerisation of UDP-D-Gal into UDP-D-Glc, was shown by 1H
NMR (Fig. 2A) to progress rapidly until equilibrium was reached
(UDP-Gal:UDP-Glc, 1:4). When UDP-6F-Gal was used as sub-
strate, the enzyme retained its activity (Fig. 2B) and the equilib-
rium (reached in 3 h) of the reaction was strongly in favour of
the gluco-conﬁgured product (UDP-6F-Gal:UDP-6F-Glc, 1:3), as
in the control reaction.
2.4. Glycosyltransferase action with ﬂuorinated and non-
ﬂuorinated donor substrates
In order to evaluate the potential of transferring the ﬂuoro-su-
gar from UDP-6F-D-Glc onto a small molecule acceptor, we exam-
ined the plant glucosyltransferase SAD10.31 This GT1 family
soluble enzyme is responsible for glycosylation of N-methylanthra-
nilic acid using UDP-D-glucose as a sugar donor, which in our sys-
tem was generated in situ from UDP-D-galactose using the
epimerase GalE (Fig. 2A). The control experiment with the natural
UDP-glucose substrate showed gradual formation of a broad dou-
blet (5.69 ppm, 1H, bd, 3J1,2 = 6.8 Hz, H1) (Fig. 2C) indicating the
formation of 1-O-(N-methylanthraniloyl)-b-D-glucopyranose (Glc-
NMA) with conversion of about 12% at time point 60 min. The
broadening of the anomeric signal is probably due to a restricted
rotation along the Ar-COOR bond at ambient temperature. Ex-
tended incubation (20 h) resulted in equilibrium with a conversion
of about 20%. Further experiments starting from Glc-NMA and
monitoring the conversion to UDP-D-glucose and N-methylanthra-
nilic acid showed that the equilibrium position for SAD10 lies at ca
30% Glc-NMA. These observations are in keeping with the ability of
at least some glycosyltransferases to generate sugar nucleotides,
not just to consume them.36,38
Subsequent investigation of the SAD10-catalysed reaction of
UDP-6F-D-Glc, generated above (Fig. 2B), and N-methylanthranilic
acid was monitored by 1H NMR, showing the anomeric proton in
UDP-6F-D-Glc (5.52 ppm, 1H, dd, 3J100 ,P = 6.8 Hz, 3J100 ,200 = 3.9 Hz,
H100) gradually becoming a set of two overlapping doublets
(5.67 ppm, 0.5H, d, 3J1,2 = 5.6 Hz, H1 and 5.66 ppm, 0.5H, d,
3J1,2 = 5.8 Hz, H1) indicative of two rotamers of 1-O-(N-methy-
lanthraniloyl)-6-deoxy-6-ﬂuoro-b-D-glucopyranose (6F-Glc-NMA)
(Fig. 2D). The conversion of UDP-6F-D-Glc into the product was
about 21% at time point 60 min. Extended incubation (20 h) re-
sulted in an equilibrium with conversion of about 31%, in keeping
with that observed for the corresponding non-ﬂuorinated sub-
strate. An analytical sample of the product was puriﬁed by a com-
bination of strong anion exchange chromatography (Poros HQ 50)
and reverse phase HPLC (C18) and the compound was character-
ised by a combination of 1H and 19F NMR and LC–MS, the latter
showing the expected molecular ion at m/z 316 ([M+H]+, 100%)and with characteristic fragment arising from sequential loss of
water molecules (m/z 298, 280, 262) and liberation of N-methy-
lanthranilate at m/z 152 ([NMA+H]+).
3. Conclusions
In summary, our efforts have identiﬁed a convenient galactoki-
nase-uridylyltransferase-epimerase approach for the generation of
UDP-6-deoxy-6-ﬂuoro-D-glucose. Initial studies also conﬁrmed
that O-glucosyltransferase SAD10 is able to utilise this sugar nucle-
otide for the production of the ﬂuoroglucosyl ester of N-methy-
lanthranilate. Combining these observations, we were able to
devise a two-stage, one-pot, multi-enzyme protocol that enables
the rapid enzymatic synthesis of milligram quantities of the de-
sired ﬂuorine labelled natural product glycoside in a matter of
minutes (Fig. 3). While the approach is dependent upon an
expedient puriﬁcation method, which we have demonstrated, the
potential for the enzymatic generation of ﬂuorosugar-containing
small molecules in a timeframe compatible with 18F -labelling is
clear.
4. Experimental
4.1. General methods
4.1.1. NMR spectroscopy
NMR spectroscopy was performed on a Bruker Avance III spec-
trometer operating at 400 MHz (1H) or 376 MHz (19F). 1H signals
were referenced to residual HDO at dH 4.70 ppm. Chemical shifts
of 1H-decoupled 19F NMR signals recorded in D2O are reported
with respect to external CFCl3 at dF 0 ppm.
4.1.2. Chemicals
3-Deoxy-3-ﬂuoro-D-glucose, 4-deoxy-4-ﬂuoro-D-glucose, 6-
deoxy-6-ﬂuoro-D-glucose and 6-deoxy-6-ﬂuoro-D-galactose were
purchased from Carbosynth. Uridine-50-triphosphate (UTP), phos-
phoenol pyruvate (PEP), adenosine-50-triphosphate (ATP), and
UDP-glucose were obtained from Sigma.
4.1.3. Enzymes
Inorganic pyrophosphatase, pyruvate kinase, uridine-50-diphos-
phogalactose 4-epimerase (GalE, from galactose-adapted yeast),
yeast hexokinase and rabbit muscle phosphoglucomutase were ob-
tained from Sigma–Aldrich. The E. coli GalK and GalPUT enzymes
were over-expressed and puriﬁed as described in Errey et al.,35
Oat root glucosyltransferase SAD10 was cloned and over-expressed
in E. coli as described in Owatworakit et al.31
4.2. Analytical and preparative HPLC-DAD
Analyses were performed on a Dionex Ultimate 3000 instru-
ment equipped with a DAD detector. Analytical samples (50 ll)
were collected at time points and quenched by addition of metha-
nol (50 ll). The samples were centrifuged at 10,000 rpm and the
supernatant was ﬁltered through 0.2 lm disc ﬁlter. A sample
(50 ll) was applied on a Poros HQ 50 strong anion-exchange col-
umn (L/D 50/10 mm, CV = 3.9 ml). The column was ﬁrst eluted
with 5 CV of 5 mM ammonium bicarbonate buffer, followed by a
linear gradient of ammonium bicarbonate from 5 mM to 250 mM
in 15 CV, then held for 5 CV, and ﬁnally back to 5 mM ammonium
bicarbonate in 3 CV at a ﬂow rate of 8 ml/min and detection with
an on-line detector to monitor A265. After multiple injections, the
column was washed with 3 CV of 1 M ammonium bicarbonate fol-
lowed by 3 CV of MQ water. Further puriﬁcation was performed on
a Dionex Ultimate 3000 instrument equipped with a DAD detector.
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5 lm C18(2) column (L/D 250/10 mm, CV = 19.6 ml) and eluted
with a gradient of acetonitrile against water at ﬂow rate 5 ml/
min: from 0% to 90% over 30 min then held for 2 min, then back
to 0% acetonitrile over 3 min and equilibrated for 6 min. The
on-line UV detector was used to monitor A240 and A270. Fractions
containing the product were pooled and freeze-dried.4.3. Enzymatic synthesis of UDP-6-deoxy-6-ﬂuoro-D-galactose
The synthesis of UDP-6-deoxy-6-ﬂuoro-galactose was per-
formed using a multi-enzymatic reaction adapted from Errey
et al.35 Brieﬂy, 6-deoxy-6-ﬂuoro-D-galactose (1 mg, 5.5 lmol),
UTP (3.4 mg, 7.7 lmol), PEP (1.68 mg, 7.2 lmol), ATP (0.08 mg,
0.15 lmol) and UDP-glucose (0.094 mg, 0.15 lmol) were dissolved
in 50 mM HEPES buffer (pH 8.0) containing 5 mM KCl and 10 mM
MgCl2 (1 ml). After addition of GalK (10 lg), GalU (10 lg), GalPUT
(10 lg), pyruvate kinase (2 U) and alkaline phosphatase (0.5 U) the
reaction was incubated at 30 C and monitored by HPLC-DAD
(Poros HQ 50). After 2 h the reaction reached about 60%
conversion. Methanol (1 ml) was added to quench the reaction
and to precipitate protein. The mixture was centrifuged at
10,000 rpm, the supernatant was ﬁltered through 0.2 lm PTFE ﬁl-
ter and the product was isolated using HPLC-DAD (Poros HQ 50).
Product containing fractions from multiple injections were pooled
and freeze-dried to give the title compound as a diammonium salt
(1.2 mg, 35%). Analytical data (1H NMR, ESI MS) were in agreement
with literature.354.4. One-pot enzymatic synthesis of 1-O-(N-
methylanthraniloyl)-6-deoxy-6-ﬂuoro-b-D-glucopyranose
The enzymatic transformations were performed in a NMR tube
in a total volume 700 ll. The reaction buffer (1 ml, 50 mM Tris–
DCl, pD 7.8) was freeze-dried and re-dissolved in D2O (1 ml).
UDP-6-deoxy-6-ﬂuoro-D-galactose (1.0 mg, 1.6 lmol, ﬁnal
c = 2.4 mM) was dissolved in (690 ll) and the 1H NMR spectrum
was acquired (no enzyme control). GalE (1 U, ﬁnal c = 1.4 U/ml; en-
zyme in 10 ll of 100 mM HEPES buffer containing 100 mM NaCl,
pH 7.0) was added and the progress of the epimerisation was mon-
itored by 1H NMR spectroscopy. After 1 h the reaction reached ap-
prox. 67% conversion to UDP-6-ﬂuoro-6-deoxy-D-glucose (further
incubation to 20 h resulted in 82% conversion). Glucosyltransferase
SAD10 (20.4 lg, ﬁnal c = 28.7 lg/ml, enzyme in 10 ll of 100 mM
Tris–HCl buffer containing 200 mM imidazole, 5% glycerol, and
300 mM NaCl, pH 7.5) was added along with N-methylanthranilic
acid (242 lg, 1.6 lmol, ﬁnal c = 2.3 mM) and the reaction was incu-
bated at 30 C. Formation of the glycoside product was monitored
over the course of 20 h by 1H NMR (D2O, 400 MHz) spectroscopy
following the diagnostic anomeric signals at dH 5.67 (0.5H, d,
3J1,2 = 5.6 Hz, H1) and 5.66 (0.5H, d, 3J1,2 = 5.8 Hz, H1). An analytical
sample of the product was puriﬁed by a combination of strong an-
ion exchange chromatography (Poros HQ 50) (peak eluting at the
void volume of the column was collected) and reverse phase HPLC
(C18) (product Rf = 16 min) and the title compound was obtained
as a white solid after freeze-drying. 1H NMR (D2O, 400 MHz): dH
7.88 (1H, m, HA-aromatic), 7.42 (1H, m, HC-aromatic), 6.76 (1H,
m, HD-aromatic), 6.60 (1H, m, HB-aromatic), 5.67 (0.5H, d,
3J1,2 = 5.6 Hz, H1), 5.66 (0.5H, d, 3J1,2 = 5.8 Hz, H1), 4.71–4.59 (2H,
m, H6a, H6b), 3.81–3.52 (4H, m, H2, H3, H4, H5), 2.77 (3H, s,
CH3). 19F NMR (D2O, 376 MHz): dF 235.9. LC–MS: peak eluting
at Rf = 5.30 min. Full ESI-MS: m/z 316 ([M+H]+, 100%). MS2 of
316: m/z 298 ([MH2O+H]+ 100%), 280 ([M2H2O+H]+, 81%), 262
([M3H2O+H]+, 36%), 152 ([NMA+H]+, 18%), 134 ([NMAOH]+,
28%).4.5. HPLC–MS/MS conﬁrmation of product formation
LC–MS analysis was performed on a Surveyor HPLC attached to
a DecaXPplus MS (both Thermo). Separation was achieved on a
50  2 mm Luna 3 l  C18(2) column (Phenomenex) using the fol-
lowing gradient of methanol versus 0.1% formic acid in water at
30 C: from 5% to 90% then hold for 1 min at ﬂow rate 0.3 ml/
min then back to 5% methanol over 0.2 min and equilibrated for
2.3 min at ﬂow rate 0.4 ml/min. Detection was performed by posi-
tive electrospray MS with spray-chamber conditions of 350 C cap-
illary temperature, 50 U sheath gas, 5 U aux gas, and a spray
voltage of 3.8 kV using a steel needle kit. In addition to full MS
from m/z 100–1500, the instrument was set up to collect data-
dependent MS2 and MS3 of the most abundant precursor ions with
collision energy of 35% and an isolation width of m/z 4.0. Dynamic
exclusion was used to ensure that after two spectra had been ac-
quired; the precursor would be ignored for 0.3 min in favor of
the next most abundant signal.Acknowledgments
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